OncoMatch/Clinical Trials/NCT04094311
Study of Out of Specification for Tisagenlecleucel
Is NCT04094311 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies CTL019 for b-cell acute lymphoblastic leukemia.
Treatment: CTL019 — This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only for Part 1, in addition to safety, key efficacy of CTL019 will also be evaluated.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04094311 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 100 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify